title: Bioequivalence comparison between hydroxyethyl starch 130/0.42/6 : 1 and hydroxyethyl starch 130/0.4/9 : 1.
abstract: OBJECTIVE
  The aim of this study was to investigate whether a recently developed low molecular, low substituted hydroxyethyl starch (HES 130/0.42/6 : 1), altered in molar substitution and C2/C6 ratio, is bioequivalent to the former standard HES preparation (130/0.4/9 : 1).
  
  
  METHODS
  The two HES solutions were infused (60g as a single dose within 30 minutes) in healthy volunteers using a randomised, crossover design. HES serum concentrations were used for computation of pharmacokinetic parameters; area under the concentration-time curve from infusion start until 24 hours thereafter (AUC(24)) and maximum serum concentration (C(max)) were the primary criteria. Haemodilution, colloid osmotic pressure and plasma viscosity were measured as secondary criteria. Pentastarch (HES 200/0.5/5:1) was investigated in the same volunteers and manner during a subsequent period.
  
  
  RESULTS
  Using non-compartmental analysis, significant differences were found for AUC(24) (45.97 +/- 8.97 mg . h/mL vs 58.32 +/- 9.23 mg . h/mL; HES 130/0.42/6 : 1 vs HES 130/0.4/9 : 1) and total apparent clearance (CL; 1.14 +/- 0.4 L/h vs 0.81 +/- 0.34 L/h). C(max) and elimination half-life (t(1/2)) were similar, while the AUC(24), t(1/2) and CL of pentastarch were significantly different from those of low substituted HES solutions.
  
  
  CONCLUSIONS
  Being equivalent with pentastarch and HES 130/0.4/9 : 1 in terms of colloid osmotic and haemodilution effect, HES 130/0.42/6 : 1 shows the fastest clearance from the circulation.
authors.affiliation: Department of Anaesthesiology and Intensive Care Medicine, Rhoen Hospital Bad Berka, Kapellendorf, Germany. gule0705@web.de
authors.forename: G
authors.initials: G
authors.lastname: Lehmann
authors.forename: G
authors.initials: G
authors.lastname: Marx
authors.forename: H
authors.initials: H
authors.lastname: Förster
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D019540:Area Under Curve; D001809:Blood Viscosity; D003404:Creatinine / Q000097:blood; D018592:Cross-Over Studies; D004311:Double-Blind Method; D006207:Half-Life; D006261:Headache / Q000139:chemically induced; D006400:Hematocrit; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics*; D007262:Infusions, Intravenous; D008297:Male; D009997:Osmotic Pressure; D010952:Plasma Substitutes / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D012996:Solutions; D013810:Therapeutic Equivalency; D013997:Time Factors
chemical_list: C485123:HES 130-0.4; C523275:HES 130-0.42-6:1; D006454:Hemoglobins; D006895:Hydroxyethyl Starch Derivatives; D010952:Plasma Substitutes; D012996:Solutions; D003404:Creatinine